Search results
30 lip 2020 · Herein we discuss the status of telomerase as a cancer target, focusing on recent advances, challenges to translate promising preclinical results, and opportunities for future directions.
7 wrz 2023 · Based on new findings and approaches, we propose a concept how long-term survival in telomerase-based cancer therapies can be significantly improved: the TICCA (Transient Immediate Complete and Combinatory Attack) strategy.
16 lip 2024 · This article presents an in-depth exploration of the roles of Telomere Repeat-binding Factors 1 and 2 (TRF1 and TRF2), and the shelterin complex, in the context of cancer biology. It emphasizes their emerging significance as potential biomarkers and targets for therapeutic intervention.
16 wrz 2022 · A study from Cancer Epidemiology, Biomarkers & Prevention found that in patients with pancreatic cancer, the pre-diagnosis length of telomeres in certain immune cells was associated with survival, with patients with shorter pre-diagnosis telomeres having significantly reduced survival.
Exploration into the specific mechanisms of telomere maintenance in cancer have led to the development of drugs such as Imetelstat (GRN163L), BIBR1532, 6-thio-dG, VE-822, and NVP-BEZ235 being investigated as therapeutic approaches for treating telomerase and ALT tumors.
5 lip 2022 · In this Review, we discuss the opportunities and limitations of targeting TMMs for cancer treatment, with a particular focus on new, repurposed and emerging therapeutics.
29 sty 2019 · Telomerase, an enzyme responsible for the maintenance of telomere, is silent in most normal somatic cells but activated in 90% of cancer cells, making it an excellent target for cancer therapy.
